From Mdwiki | Soft-tissue sarcoma | |
|---|---|
![]() | |
| Undifferentiated soft tissue sarcoma in left lung of young child | |
A soft-tissue sarcoma (STS) is a malignant tumour, a type of cancer, that develops in soft tissue.[1] It is typically a painless mass that grows slowly over months or years.[1] It may be superficial or deep-seated.[1]
Diagnosis is by biopsy.[2] Treatment may include, surgery, radiotherapy, chemotherapy, and targeted drug therapy.[3]
The World Health Organization lists more than fifty subtypes.[2][4]
| Tissue of Origin | Type of Cancer | Usual Location in the Body |
|---|---|---|
| Fibrous tissue | Fibrosarcoma | Arms, legs, trunk |
| Malignant fibrous hystiocytoma | Legs | |
| Dermatofibrosarcoma | Trunk | |
| Fat | Liposarcoma | Arms, legs, trunk |
| Muscle (striated) | Rhabdomyosarcoma | Arms, legs |
| Muscle (smooth) | Leiomyosarcoma | Uterus, digestive tract |
| Blood vessels | Hemangiosarcoma | Arms, legs, trunk |
| Kaposi's sarcoma | Legs, trunk | |
| Lymph vessels | Lymphangiosarcoma | Arms |
| Synovial tissue[lower-alpha 1] | Synovial sarcoma | Legs |
| Peripheral nerves | Malignant peripheral nerve sheath tumour / Neurofibrosarcoma | Arms, legs, trunk |
| Cartilage and bone-forming tissue | Extraskeletal chondrosarcoma | Legs |
| Extraskeletal osteosarcoma | Legs, trunk (not involving the bone) |
| Tissue of Origin | Type of Cancer | Usual Location in the Body | Most common ages |
|---|---|---|---|
| Muscle (striated) | Rhabdomyosarcoma | ||
| Embryonal | Head and neck, genitourinary tract | Infant–4 | |
| Alveolar soft part sarcoma | Arms, legs, head, and neck | Infant–19 | |
| Muscle (smooth) | Leiomyosarcoma | Trunk | 15–19 |
| Fibrous tissue | Fibrosarcoma | Arms and legs | 15–19 |
| Malignant fibrous histiocytoma | Legs | 15–19 | |
| Dermatofibrosarcoma | Trunk | 15–19 | |
| Fat | Liposarcoma | Arms and Legs | 15–19 |
| Blood vessels | Infantile hemangio-pericytoma | Arms, legs, trunk, head, and neck | Infant–4 |
| Synovial tissue[lower-alpha 1] | Synovial sarcoma | Legs, arms, and trunk | 15–19 |
| Peripheral nerves | Malignant peripheral nerve sheath tumors (also called neurofibrosarcomas, malignant schwannomas, and neurogenic sarcomas) | Arms, legs, and trunk | 15–19 |
| Muscular nerves | Alveolar soft part sarcoma | Arms and legs | Infant–19 |
| Cartilage and bone-forming tissue | Extraskeletal myxoid chondrosarcoma | Legs | 10–14 |
| Extraskeletal mesenchymal | Legs | 10–14 |
An earlier version of this article was taken from the US National Cancer Center's Cancer Information Service.
In their early stages, soft-tissue sarcomas usually do not cause symptoms. Because soft tissue is relatively elastic, tumors can grow rather large, pushing aside normal tissue, before they are felt or cause any problems. The first noticeable symptom is usually a painless lump or swelling. As the tumor grows, it may cause other symptoms, such as pain or soreness, as it presses against nearby nerves and muscles. If in the abdomen it can cause abdominal pains commonly mistaken for menstrual cramps, indigestion, or cause constipation.[citation needed]
Most soft-tissue sarcomas are not associated with any known risk factors or identifiable cause. There are some exceptions:

The only reliable way to determine whether a soft-tissue tumour is benign or malignant is through a biopsy. The two methods for acquisition of tumour tissue for cytopathological analysis are:
A pathologist examines the tissue under a microscope. If cancer is present, the pathologist can usually determine the type of cancer and its grade. Here, 'grade' refers to a scale used to represent concisely the predicted growth rate of the tumour and its tendency to spread, and this is determined by the degree to which the cancer cells appear abnormal when examined under a microscope. Low-grade sarcomas, although cancerous, are defined as those that are less likely to metastasise. High-grade sarcomas are defined as those more likely to spread to other parts of the body. For soft-tissue sarcoma, the two histological grading systems are the National Cancer Institute system and the French Federation of Cancer Centers Sarcoma Group system.[6][7][8]
Soft-tissue sarcomas commonly originate in the upper body, in the shoulder or upper chest. Some symptoms are uneven posture, pain in the trapezius muscle, and cervical inflexibility [difficulty in turning the head].[citation needed]
The most common site to which soft-tissue sarcoma spreads is the lungs.[citation needed]
In general, treatment for soft-tissue sarcomas depends on the stage of the cancer. The stage of the sarcoma is based on the size and grade of the tumor, and whether the cancer has spread to the lymph nodes or other parts of the body (metastasized). Treatment options for soft-tissue sarcomas include surgery, radiotherapy, chemotherapy, and targeted drug therapy.[3]
Soft-tissue sarcomas are relatively uncommon cancers. They account for less than 1% of all new cancer cases each year. This may be because cells in soft tissue, in contrast to tissues that more commonly give rise to malignancies, are not continuously dividing cells.[citation needed]
In 2006, about 9,500 new cases were diagnosed in the United States.[12] Soft-tissue sarcomas are more commonly found in older patients (>50 years old), although in children and adolescents under age 20, certain histologies are common (rhabdomyosarcoma, synovial sarcoma).[citation needed]
Around 3,300 people were diagnosed with soft-tissue sarcoma in the UK in 2011.[13]
The research in soft tissue sarcoma requires lot of effort because of its rarity and needs immense collaboration. In year 2019, few notable researches have been presented but mostly failed. However, we are learning that they can't be lumped together and each sarcoma is a different disease.[14]
Immunotherapy may have an upcoming role in treating soft tissue sarcomas like alveolar soft part sarcoma and pleomorphic undifferentiated sarcoma. In a report by Dr. Sameer Rastogi et al., a patient with advanced pleomorphic undifferentiated sarcoma had excellent response to combination of pembrolizumab and pazopanib.[15]
| Classification |
|---|
Categories: [Connective/soft tissue tumors and sarcomas] [Sarcoma] [Soft tissue tumor]